BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2060 related articles for article (PubMed ID: 31378236)

  • 1. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
    Duma N; Santana-Davila R; Molina JR
    Mayo Clin Proc; 2019 Aug; 94(8):1623-1640. PubMed ID: 31378236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update 2020: Management of Non-Small Cell Lung Cancer.
    Alexander M; Kim SY; Cheng H
    Lung; 2020 Dec; 198(6):897-907. PubMed ID: 33175991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updates in non-small cell lung cancer.
    Walker S
    Clin J Oncol Nurs; 2008 Aug; 12(4):587-96. PubMed ID: 18676326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
    Arbour KC; Riely GJ
    JAMA; 2019 Aug; 322(8):764-774. PubMed ID: 31454018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive markers in the adjuvant therapy of non-small cell lung cancer.
    Filipits M; Pirker R
    Lung Cancer; 2011 Dec; 74(3):355-63. PubMed ID: 21885151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shifting paradigms in non-small cell lung cancer: an evolving therapeutic landscape.
    Riessk J
    Am J Manag Care; 2013 Dec; 19(19 Suppl):s390-7. PubMed ID: 24494720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
    BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodality Therapy for NSCLC.
    Du L; Waqar SN; Morgensztern D
    Cancer Treat Res; 2016; 170():151-63. PubMed ID: 27535393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
    Rassy E; Mezquita L; Remon J; Besse B
    Immunotherapy; 2019 Sep; 11(13):1149-1160. PubMed ID: 31361172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives.
    Antoni D; Mornex F
    Curr Opin Oncol; 2016 Mar; 28(2):104-9. PubMed ID: 26848885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
    Gui Q; Liu J; Li D; Xu C
    World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
    Nagasaka M; Gadgeel SM
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):63-70. PubMed ID: 29168933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
    Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
    Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
    ;
    Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):539-574. PubMed ID: 37460438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
    Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
    J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy for lung cancer].
    Ostoros G
    Magy Onkol; 2017 Jun; 61(2):153-157. PubMed ID: 28585617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in systemic therapy for non-small cell lung cancer.
    Miller M; Hanna N
    BMJ; 2021 Nov; 375():n2363. PubMed ID: 34753715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 103.